China’s Iron Ore Buyer Pressures Mining Giants as New Supply Shifts Market Power 
Nike Stock Rises After CEO Elliott Hill Buys $1 Million in Shares 
Anghami Stock Soars After Strong H1 2025 Results, Revenue Nearly Doubles on OSN+ Integration 
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy 
Boeing Secures Multi-Billion Dollar Defense Contracts for F-15IA Jets and E-4B Aircraft Support 
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 
Air China Orders 60 Airbus A320neo Jets in $9.5 Billion Deal as Airbus Strengthens Grip on China Market 
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring 
Royalty Pharma Stock Rises After Acquiring Full Evrysdi Royalty Rights from PTC Therapeutics 
ByteDance Plans Massive AI Chip Spending Boost as Nvidia Demand Grows in China 
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital 
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions 
Vanda Pharmaceuticals Wins FDA Approval for New Motion Sickness Drug After Four Decades 
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro 
SoftBank Completes $41 Billion OpenAI Investment in Historic AI Funding Round 
L&F Tesla Battery Supply Deal Value Drops Sharply Amid EV Market Slowdown 
Boeing Secures $8.6 Billion Pentagon Contract for F-15 Jets for Israel 
EAST RUTHERFORD, N.J., Oct. 12, 2017 -- Cambrex Corporation (NYSE:CBM), the leading manufacturer of small molecule innovator and generic Active Pharmaceutical Ingredients (APIs), today announced that it has made a number of investments, in both R&D and manufacturing capabilities to support the development and production of generic APIs, at its site in Paullo, Milan, Italy.
The investments include the installation of development and analytical equipment to support the development of highly potent APIs (HPAPIs), as well as a new 2,800 liter hydrogenator and 1,500mm diameter centrifuge, for increased flexibility and capacity within the manufacturing plant. All equipment will be installed and validated by the end of 2017.
“We have seen increased growth of activity among highly potent molecules in the past decade for use in therapeutics for cancer and other indications, and it is now becoming more appropriate in the generic API business as patents on these begin to expire,” commented Aldo Magnini, Managing Director, Cambrex Milan. “This investment is consistent with the Cambrex strategic plan to increase the company’s small molecule development and manufacturing capabilities, ensuring our facilities continue to meet the future demands of the industry.”
This investment comes after the installation of a new pilot plant at the site in 2017, and recent announcements of expansions across the Cambrex network of manufacturing sites, including the construction of a $24M, 4,500 sq. ft. highly potent API manufacturing facility at its Charles City, Iowa site, which is due to open in 2019.
About Cambrex
Cambrex Corporation is an innovative life sciences company that provides products, services and technologies to accelerate the development and commercialization of small molecule therapeutics. The company offers Active Pharmaceutical Ingredients (APIs), advanced intermediates and enhanced drug delivery products for branded and generic pharmaceuticals. Development and manufacturing capabilities include enzymatic biotransformations, high potency APIs, high energy chemical synthesis and controlled substances. For more information, please visit www.cambrex.com
Contact:
Alex Maw
Director, Marketing and Communications
Tel: +44 7803 443 155
Email: [email protected]
